Search results Search for: Search Refine your results by duration: Any Under 5 mins Under 20 mins Over 20 mins Sort by: Relevance Views Date Cost effectiveness analysis of PD-L1 testing in NSCLC - IVD vs LDT Jason Hurwitz, BA, MA, Phd; Shannon Vaffis, MPH, Phd; Amy Grizzle, BA, Pharm D This webinar will share compelling research that evaluated the cost-effectiveness of PD-L1 testing with an in vitro diagnostic (IVD) compared to a lab... 8 months ago | 45 mins ALK IHC vs ISH and ALK Inhibitors in Treatment of ALK-Positive Advanced NSCLC Prof Dr EMD (Ed) Schuuring and Prof Dr HJM (Harry) Groen ALK IHC vs ISH and ALK Inhibitors in Treatment of ALK-Positive Advanced NSCLC presented by Prof Dr. EMD (Ed) Schuuring, Clinical Scientist in Molecula... 4 years ago | 32 mins Battle of the ALKs: ALK IHC vs. ISH in treatment of ALK-positive advanced NSCLC Prof Dr EMD (Ed) Schuuring & Prof Dr HJM (Harry) Groen Join Dr. Ed Schuuring and Dr. Harry Groen, University Medical Center Groningen, The Netherlands, to explore the role of immunohistochemistry (IHC) in ... 4 years ago | 56 mins Module 3: Ventana PD-L1 (SP263) Assay NSCLC Guided Digital Case Review Dr. Dorothy Hayden, Pathologist at Roche Tissue Diagnostics This series of videos is provided as a resource for individuals in countries where VENTANA PD-L1 (SP263) Assay is approved for use for non-small cell ... 3 years ago | 71 mins ROS1 in NSCLC Pathology and Prediction Dr. Erik Thunnissen, FBJM ROS1 in NSCLC Pathology and Prediction presented by Dr. Erik Thunnissen, FBJM, Department of Pathology, VU University Medical Center Amsterdam, The Ne... 4 years ago | 12 mins Module 1: Ventana PD-L1 (SP263) NSCLC Assay Overview Dr. Dorothy Hayden, Pathologist at Roche Tissue Diagnostics This series of videos is provided as a resource for individuals in countries where VENTANA PD-L1 (SP263) Assay is approved for use for non-small cell ... 3 years ago | 11 mins Creating 3D Organoid Models of Small Cell Lung Cancer Amanda Linkous, Ph.D. Small cell lung cancer (SCLC) accounts for approximately 15% of all lung cancer cases and is clinically more aggressive than non-small cell lung cance... 1 year ago | 39 mins Key Notables on IHC Interpretation of PD-L1 SP263 on FNA samples Dr. Dorothy Hayden, Pathologist, Companion Diagnostic, at Roche Tissue Diagnostics Dr. Dorothy Hayden, Staff Pathologist, Companion Diagnostics with Roche Tissue Diagnostics, will discuss key insights that can be applied to successfu... 2 years ago | 40 mins Module 2: Ventana PD-L1 (SP263) Assay NSCLC Evaluation Education Dr. Dorothy Hayden, Pathologist at Roche Tissue Diagnostics This series of videos is provided as a resource for individuals in countries where VENTANA PD-L1 (SP263) Assay is approved for use for non-small cell ... 3 years ago | 18 mins Lung Cancer Biomarker Testing Dr. Paul A. Bunn Jr, MD Lung Cancer Biomarker Testing presented by Dr. Paul A. Bunn Jr, MD, Distinguished Professor and Dudley Endowed Chair University of Colorado Cancer Cen... 4 years ago | 20 mins
